BRPI0520530A2 - método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb - Google Patents

método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb

Info

Publication number
BRPI0520530A2
BRPI0520530A2 BRPI0520530-1A BRPI0520530A BRPI0520530A2 BR PI0520530 A2 BRPI0520530 A2 BR PI0520530A2 BR PI0520530 A BRPI0520530 A BR PI0520530A BR PI0520530 A2 BRPI0520530 A2 BR PI0520530A2
Authority
BR
Brazil
Prior art keywords
patient
predicting
monitoring
response
erbb receptor
Prior art date
Application number
BRPI0520530-1A
Other languages
English (en)
Inventor
Kazuto Nishio
Hideharu Kimura
Kazuo Kasahara
Original Assignee
Astrazeneca Uk Ltd
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd, Nat Cancer Ct filed Critical Astrazeneca Uk Ltd
Publication of BRPI0520530A2 publication Critical patent/BRPI0520530A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Resumo de patente de Invenção: "MéTODO PARA PREDIZER OU MONITORAR A RESPOSTA DE UM PACIENTE A UMA DROGA RECEPTORA DO ERBB". A presente invenção fornece um método para detecção de mutações do receptor do ErbE compreendendo as etapas de fornecer uma amostra de fluido biológico de um paciente; extração do DNA da dita amostra; e a avaliação do dito DNA quanto à presença de uma ou mais mutações que alteram a atividade da tirosina quinase no receptor.
BRPI0520530-1A 2005-10-05 2005-10-20 método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb BRPI0520530A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2005003823 2005-10-05
PCT/GB2005/004036 WO2007039705A1 (en) 2005-10-05 2005-10-20 Method to predict or monitor the response of a patient to an erbb receptor drug

Publications (1)

Publication Number Publication Date
BRPI0520530A2 true BRPI0520530A2 (pt) 2009-09-29

Family

ID=36114238

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520530-1A BRPI0520530A2 (pt) 2005-10-05 2005-10-20 método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb

Country Status (14)

Country Link
US (1) US20080286785A1 (pt)
EP (1) EP1931798A1 (pt)
JP (1) JP2009511008A (pt)
KR (1) KR20080028857A (pt)
CN (1) CN101351563A (pt)
AU (1) AU2005337051A1 (pt)
BR (1) BRPI0520530A2 (pt)
CA (1) CA2624613A1 (pt)
IL (1) IL189705A0 (pt)
NO (1) NO20081198L (pt)
NZ (1) NZ566387A (pt)
TW (1) TW200714716A (pt)
WO (1) WO2007039705A1 (pt)
ZA (1) ZA200802854B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
DK2433124T3 (en) * 2009-05-19 2017-06-19 Vivia Biotech Sl PROCEDURES FOR PROVIDING PERSONALIZED MEDICAL EX VIVO TESTS FOR HEMATOLOGICAL NEOPLASMS
EP2510110A1 (en) 2009-11-13 2012-10-17 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
BR112012012160B1 (pt) * 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
KR101536318B1 (ko) * 2010-10-29 2015-07-13 아크레이 가부시키가이샤 Ｅｇｆｒ 유전자의 다형(多型) 검출용 프로브, 증폭용 프라이머 및 그 용도
WO2012065071A2 (en) * 2010-11-12 2012-05-18 The Broad Institute Of Mit And Harvard Methods of predicting response to egfr antibody therapy
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
CN107419018B (zh) * 2012-02-16 2020-09-04 江苏宏微特斯医药科技有限公司 一种基于Blocker引物和ARMS引物检测基因突变的方法和试剂盒
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US9873913B2 (en) * 2013-03-08 2018-01-23 Roche Molecular Systems, Inc. Mutation testing
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US9994914B2 (en) 2014-10-09 2018-06-12 Roche Molecular Systems, Inc. Mutation in the epidermal growth factor receptor kinase domain
GB201507202D0 (en) 2015-04-28 2015-06-10 Stfc Science & Technology Receptor tyosine kinase biomarkers
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
US10624874B2 (en) * 2017-01-10 2020-04-21 Zhejiang Jiachi Development Pharmaceuticals Ltd Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9403953D0 (sv) * 1994-07-15 1994-11-16 Pharmacia Biotech Ab Sequence-based diagnosis
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
GB9812768D0 (en) * 1998-06-13 1998-08-12 Zeneca Ltd Methods
CN101056990A (zh) * 2004-03-01 2007-10-17 芝加哥大学 表皮生长因子受体基因启动子的多态性
EP3611273A1 (en) * 2004-03-31 2020-02-19 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP3042964A1 (en) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
US20060223178A1 (en) * 2005-04-05 2006-10-05 Tom Barber Devices and methods for magnetic enrichment of cells and other particles

Also Published As

Publication number Publication date
IL189705A0 (en) 2008-06-05
ZA200802854B (en) 2009-06-24
EP1931798A1 (en) 2008-06-18
CN101351563A (zh) 2009-01-21
WO2007039705A1 (en) 2007-04-12
CA2624613A1 (en) 2007-04-12
TW200714716A (en) 2007-04-16
US20080286785A1 (en) 2008-11-20
KR20080028857A (ko) 2008-04-01
NO20081198L (no) 2008-06-30
NZ566387A (en) 2010-05-28
JP2009511008A (ja) 2009-03-19
AU2005337051A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
NO20081198L (no) Fremgangsmate for a predikere eller monitorere en pasients respons til et medikament rettet mot en ErbB-reseptor
WO2007089731A3 (en) Ocular fluid markers
WO2009117122A8 (en) Genetic analysis
BRPI0914020A2 (pt) método para detecção e/ou o diagnóstico de uma ou mais causas de distúrbio do ritmo do coração, sistema para a detecção e/ou o tratamento de uma ou mais causas de um distúrbio do ritmo do coração, método para o tratamento de distúrbio do ritmo do coração, dispositivo sensor ajustável para detectar distúrbios do ritmo do coração, método para a detecção e/ou o diagnóstico de uma ou mais causas de um distúrbio do ritmo biológico, sistema para a detecção e/ou o tratamento de uma ou mais causas de um distúrbio do ritmo biológico e método para o tratamento de um distúrbio do ritmo biológico
BRPI0508286A (pt) métodos para determinar a possibilidade de efetividade de um tratamento seletivo de receptor de fator de crescimento epidérmico em um paciente, para tratar um paciente e para selecionar um composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, sonda, kit, composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, composição farmacêutica, ácido nucléico e proteìna isolada
EP2506914A4 (en) ANALYTICAL MONITORING AND LIQUID DISPENSING SYSTEM
DK2114990T5 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
WO2007070376A3 (en) Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis
MA31991B1 (fr) Anticorps contre le virus de la grippe et procedes pour leur utilisation
EP2029009A4 (en) EEG ANALYSIS SYSTEM
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
EP3330703A3 (en) Lipoprotein analysis by differential charged-particle mobility
WO2009041501A1 (ja) ヘルペスウイルスの潜伏感染に関与する因子及びその利用
BR112013013457A2 (pt) métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições
BR112022008391A2 (pt) Sistemas de ensaio de fluxo lateral e métodos para quantificação de amostra biológica
Egashira et al. Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs
BR112012007812A2 (pt) métodos de quantificação de organismos-alvo e criação de plantas de algodão resistentes reniforme.
EA200701602A1 (ru) Способ прогнозирования психических заболеваний, например аутизма и церебрального паралича
Campisi et al. Unveiling the geroprotective potential of Monarda didyma L.: insights from in vitro studies and a randomized clinical trial on slowing biological aging and improving quality of life
Mouri et al. The ubiquitination of serotonin transporter in lymphoblasts derived from fluvoxamine-resistant depression patients
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
Maurer Demands on scientific studies in clinical toxicology
WO2002010456A3 (en) Multiparameter analysis for predictive medicine
EP2151496A4 (en) METHOD FOR EVALUATING ACTIVE SENSITIVITY BY ANALYSIS OF THE POMC GENE
EP1670497A4 (en) METHOD FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C EPSILON (PKC Ε) AND METHOD FOR TREATING THEREOF CONVERTING DERIVED GLUCOSE METABOLISM

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA, EM NOME DE TODOS OS DEPOSITANTES; OU SEGUNDO O PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O (OS) INTERESSADO (S), DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.